Dominari (DOMH) Competitors $5.26 +0.01 (+0.19%) As of 12:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. XOMA, LXRX, VSTM, VNDA, CDXS, AGEN, ACHV, IRWD, SGMO, and FBIOShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include XOMA Royalty (XOMA), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Agenus (AGEN), Achieve Life Sciences (ACHV), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), and Fortress Biotech (FBIO). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors XOMA Royalty Lexicon Pharmaceuticals Verastem Vanda Pharmaceuticals Codexis Agenus Achieve Life Sciences Ironwood Pharmaceuticals Sangamo Therapeutics Fortress Biotech XOMA Royalty (NASDAQ:XOMA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Do institutionals and insiders believe in XOMA or DOMH? 95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by company insiders. Comparatively, 33.0% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer XOMA or DOMH? XOMA Royalty currently has a consensus price target of $69.50, indicating a potential upside of 158.85%. Given XOMA Royalty's stronger consensus rating and higher possible upside, equities analysts plainly believe XOMA Royalty is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, XOMA or DOMH? XOMA Royalty has higher revenue and earnings than Dominari. XOMA Royalty is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA Royalty$28.49M11.28-$13.82M-$1.15-23.35Dominari$18.15M4.24-$14.70M-$4.50-1.17 Does the media prefer XOMA or DOMH? In the previous week, XOMA Royalty had 7 more articles in the media than Dominari. MarketBeat recorded 7 mentions for XOMA Royalty and 0 mentions for Dominari. XOMA Royalty's average media sentiment score of 0.54 beat Dominari's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media. Company Overall Sentiment XOMA Royalty Positive Dominari Neutral Is XOMA or DOMH more profitable? XOMA Royalty has a net margin of -13.04% compared to Dominari's net margin of -167.73%. XOMA Royalty's return on equity of -12.43% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets XOMA Royalty-13.04% -12.43% -4.85% Dominari -167.73%-91.67%-77.80% Which has more risk & volatility, XOMA or DOMH? XOMA Royalty has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. SummaryXOMA Royalty beats Dominari on 14 of the 16 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.01M$2.42B$5.50B$9.03BDividend YieldN/A1.77%5.39%4.11%P/E Ratio-1.178.9627.5220.10Price / Sales4.24468.23397.84108.06Price / CashN/A151.5836.1356.90Price / Book0.924.627.985.65Net Income-$14.70M$31.34M$3.16B$248.47M7 Day Performance-10.85%0.65%1.91%2.80%1 Month Performance21.20%7.60%4.17%5.62%1 Year Performance161.69%1.55%35.76%21.20% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.9665 of 5 stars$5.26+0.2%N/A+163.8%$77.01M$18.15M-1.174Gap UpXOMAXOMA Royalty4.432 of 5 stars$27.27+4.0%$69.50+154.9%+6.0%$328.09M$28.49M-23.8310Gap UpLXRXLexicon Pharmaceuticals2.4912 of 5 stars$0.75+1.8%$3.67+390.9%-42.8%$270.03M$31.08M-1.46140News CoverageVSTMVerastem2.8331 of 5 stars$4.88+5.5%$13.63+179.5%+65.2%$266.78M$10K-1.5250VNDAVanda Pharmaceuticals4.6272 of 5 stars$4.50+0.7%$16.50+266.7%-7.2%$265.72M$198.77M-6.01290CDXSCodexis3.6851 of 5 stars$2.49+5.5%$11.00+341.8%-2.8%$205.04M$49.82M-2.50250Positive NewsAGENAgenus4.3134 of 5 stars$5.02+4.6%$14.00+178.9%-61.4%$137.27M$103.46M-0.58440ACHVAchieve Life Sciences1.603 of 5 stars$3.75-2.2%$14.33+281.8%-50.8%$128.87MN/A-2.7720IRWDIronwood Pharmaceuticals4.792 of 5 stars$0.69+2.0%$4.78+596.3%-88.1%$110.52M$351.41M-3.41220SGMOSangamo Therapeutics2.7396 of 5 stars$0.47+7.6%$4.50+867.7%+67.1%$107.49M$57.80M-1.18480FBIOFortress Biotech2.6117 of 5 stars$1.73+0.9%$21.00+1,117.4%+9.6%$51.01M$57.67M-0.77170Gap Up Related Companies and Tools Related Companies XOMA Royalty Competitors Lexicon Pharmaceuticals Competitors Verastem Competitors Vanda Pharmaceuticals Competitors Codexis Competitors Agenus Competitors Achieve Life Sciences Competitors Ironwood Pharmaceuticals Competitors Sangamo Therapeutics Competitors Fortress Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.